The role of growth hormone device optimisation in patient-reported outcomes: Real-world evidence from South Korea

초록

https://www.endocrine-abstracts.org/ea/0070/ea0070aep1069.htm. Growth hormone (GH) therapy (GHT) requires long-term commitment to daily sc GH injections that may present adherence challenges. Patient preference and adherence have been shown to be affected by delivery devices in association with convenience of administration, level of injection-site pain, confidence in correct dose administration and satisfaction with the device. This survey investigated if switching GH device ? from NordiLet/others to NordiFlex ? improved patient-reported preference, satisfaction, ease of use and adherence in paediatric patients receiving GHT in South Korea. Patients aged 4 to ≤ 18 years receiving GHT from paediatric clinics in South Korea between January and July 2019 were surveyed. Participants were current users of NordiFlex for 4?24 weeks who had previously used NordiLet or other GH devices for ≥ 12 weeks before switching. Patients/caregivers compared the subjective benefits of NordiFlex vs previous device in a 25-question survey comprising four domains: ease of use, self-efficacy, minimal disruption of daily life, feelings about injections. Patients responded on a 5-point Likert scale (?2 strongly disagree, ?1 disagree, 0 no difference, 1 agree, 2 strongly agree). The survey also included questions about preference for, as well as satisfaction, perceived ease of use and self-reported adherence with, NordiFlex vs previous device. 94 patients were included in the survey. 91.5% previously used NordiLet; the rest used another device. Only 8.5% self-administered GH. A significantly greater proportion of patients preferred, and were more satisfied with, NordiFlex vs previous device; mean score: 0.65 (95% CI : 0.41; 0.88) and 0.61 (95% CI : 0.36; 0.85), respectively. Similarly, patients reported greater perceived ease of use and fewer missed injections with NordiFlex vs previous device; mean score: 0.49 (95% CI : 0.26; 0.72) and 0.20 (95% CI : 0.06;0.34), respectively. Bivaria